abstract: Menstruation involves the shedding of the functional layer of the endometrium in the absence of pregnancy. At sites where tissue shedding is complete, re-epithelialization of the tissue is essential for repair and termination of bleeding. The complement of growth factors that mediate post-menstrual endometrial repair are yet to be completely elucidated. Galectins regulate many cell functions important for post-menstrual repair, such as cell adhesion and migration. Galectin-7 has a well characterized role in re-epithelialization and wound healing. We hypothesized that galectin-7 would be important in re-epithelialization during post-menstrual repair. We aimed to identify endometrial expression of galectin-7 in women undergoing normal endometrial repair and in women with amenorrhoea who do not experience endometrial breakdown and repair, and to determine whether galectin-7 enhances endometrial re-epithelialization in vitro. Galectin-7 immunolocalized to the endometrial luminal and glandular epithelium during the late secretory and menstrual phases, and to decidualized stroma in regions exhibiting tissue breakdown. Immunostaining intensity was significantly reduced in the endometrium of women with amenorrhoea compared with normally cycling woman. ELISA identified galectin-7 in menstrual fluid at significantly elevated levels compared with matched peripheral plasma. Exogenous galectin-7 (2.5 mg/ml) significantly enhanced endometrial epithelial wound repair in vitro; this was abrogated by inhibition of integrin binding. Galectin-7 elevated epithelial expression of extracellular matrix-related molecules likely involved in repair including b-catenin, contactin and TGF-b1. In conclusion, galectin-7 is produced by the premenstrual and menstrual endometrium, where it accumulates in menstrual fluid and likely acts as a paracrine factor to facilitate post-menstrual endometrial re-epithelialization.
Introduction
Menstruation, the shedding of the functional layer of the endometrium in the absence of pregnancy, is a distinctive phenomenon experienced by only a few species (Finn, 1987; Rasweiler, 1991; Rasweiler and de Bonilla, 1992; Martin, 2007) , particularly women. The menstrual cascade is initiated upon withdrawal of progesterone support concomitant with the demise of the corpus luteum (Jabbour et al., 2006) in the late secretory phase of non-conception cycles. Loss of the anti-inflammatory protection of progesterone leads to activation of inflammatory signalling within the tissue (Evans and Salamonsen, 2013) . Enhanced leukocyte recruitment with increased activation and production of degradative enzymes, increased reactive oxygen species, a hypoxic environment and inflammation lead to focal tissue destruction and bleeding, which characterizes menstruation (Sugino et al., 2004; Slayden and Brenner, 2006; Evans and Salamonsen, 2012) . At sites where tissue shedding is complete, re-epithelialization of the tissue commences. This is essential for tissue homeostasis and termination of bleeding. Re-epithelialization is dependent of phenotypic changes in leukocytes within the tissue (from pro-to anti-inflammatory), growth factor signalling and dynamic alterations in extracellular matrix (ECM) factors. All of these facilitate restoration of tissue integrity and thus prepare the endometrium for the next menstrual cycle (Evans et al., 2011) . The complement of growth factors that mediate post-menstrual endometrial repair and the matrix factors they may alter have yet to be fully elucidated.
they have a wide variety of functions including homeostasis, cell adhesion and migration, immune cell activation, apoptosis, differentiation and hormone production (Elola et al., 2007; Rabinovich and Toscano, 2009; Fitzgerald et al., 2010) . Galectins lack a typical secretion signal peptide (Nakahara and Raz, 2006) : they are secreted by a non-classical, endoplasmic reticulum-independent pathway (Elola et al., 2007) . It is currently hypothesized that they are released by an unusual route, which requires intact carbohydrate binding of the secreted protein (Elola et al., 2007; Rabinovich and Toscano, 2009) .
The galectin family has many and varied roles in reproduction. Galectin-7 is a 15-kDa protein originally identified in the epidermis. It is generally expressed by epithelial cells and localized to areas of cellcell contact (Elola et al., 2007) . It is a prototype galectin found as both a monomer and a dimer (Leonidas et al., 1998) ; unlike most mammalian galectins, it is known to exist as a monomer in solution (Leonidas et al., 1998) . Galectin-7 is secreted by keratinocytes (Saussez and Kiss, 2006) suggesting it may have functions in the skin.
Galectin-7 has a well-characterized role in tissue repair; it accelerates re-epithelialization of corneal wounds more efficiently than most known growth factors (Cao et al., 2002 (Cao et al., , 2003 and silencing galectin-7 impairs skin and kidney epithelial wound repair (Gendronneau et al., 2008; Rondanino et al., 2011) . The mechanism by which galectin-7 accelerates re-epithelialization is not well understood, but it is likely via interactions with integrins as galectins cooperate closely with integrins (Saussez and Kiss, 2006) . Certainly, HeLa cells transfected with galectin-7 show a 4-fold increase in integrin a1 mRNA expression . Galectins are also known to modulate cell-matrix adhesion proteins (Elola et al., 2007) , although nothing of this is known for galectin-7.
Galectin-7 was recently identified in the uterine luminal epithelium during the menstrual cycle (Menkhorst et al., 2014) . Given galectin-7 ′ s well-characterized role in epithelial migration and wound healing we hypothesized that galectin-7 may be important in the re-epithelialization of the uterine luminal epithelium during post-menstrual repair. We aimed to identify and compare endometrial expression of galectin-7 in women with normal endometrial repair versus women with amenorrhoea who do not experience endometrial breakdown and repair. We also established that galectin-7 enhances endometrial re-epithelialization and investigated the mechanism by which galectin-7 mediates endometrial epithelial wound repair.
Materials and Methods

Ethics statement
Ethical approval was obtained from Institutional Ethics Committees at Southern Health for all tissue collections. Written informed consent was obtained from all subjects prior to sample collection.
Tissue collection and patient details
Endometrial biopsies for immunohistochemistry were collected from normally cycling women during the late secretory (n ¼ 6) or menstrual (n ¼ 9) phase of the cycle or from women with amenorrhoea (n ¼ 10). In the amenorrhoea group, four women had no known pathology, one woman had uterine adhesions, one woman had a fibroid and four women had PCOS. All women were under 45 years of age and had not received steroid hormone therapy in the last 6 months. The biopsies were fixed in 10% formalin for 24 h prior to processing to paraffin wax.
Human endometrium for culture was obtained by curettage from normal cycling women following laparoscopic sterilization or assessment of tubal patency. All women were under 40 years of age: none had used hormonal treatment in the preceding 3 months and none had endometriosis or other uterine pathologies. All women were determined to have a normal endometrium by histology. Menstrual cycle stage in normal cycling women was determined by patient testimony and confirmed by histological dating. All tissues used in this study were collected between Days 10 and 14 of regular 28-to 32-day menstrual cycles. Tissues were immediately processed for cell isolation.
Menstrual fluid and peripheral blood plasma collection
Women were recruited by self-nomination for matched menstrual fluid and peripheral blood plasma collection. On the second day of menses, each woman wore a lunette menstrual cup for 4 -6 h. Menstrual fluid was collected into a 50-ml centrifuge tube, gross volume recorded and then centrifuged at 1500 rpm for 10 min to remove blood and cellular debris. The plasma fraction from each sample was removed and stored at 2808C. Peripheral blood plasma was collected from the same woman immediately prior to removal of the menstrual cup (matched peripheral blood sample). About 20 ml of peripheral blood was collected into lithium heparin tubes. Peripheral blood samples were then centrifuged to remove blood cells; the plasma fraction was removed and stored as above.
Immunohistochemistry
Immunohistochemistry was performed on previously collected endometrial tissues chosen from our archived material. 5 mm tissue sections were placed onto superfrost slides. Tissue sections were dewaxed in Histosol (Sigma Chemical Co.; St Louis, MO, USA) and rehydrated through descending grades of alcohol (95-70%) to distilled water (dH 2 O). Antigen retrieval was performed by heating sections in 0.01 M pH 6 citrate buffer for 5 min. Endogenous peroxidise activity was blocked by incubation in 3% hydrogen peroxide for 5 min at room temperature. Non-specific binding was blocked by incubation of tissue sections in non-immune serum (10% horse serum, 2% human serum, Tris buffered saline [TBS] ). Sections were subsequently incubated overnight at 48C with anti-galectin-7 antibody (0.5 mg/ ml, R&D systems) or goat IgG (negative control, Dako). Sections were extensively washed in TBS-0.6% Tween 20 followed by incubation with biotinylated horse anti-goat antibody (1:200, Dako) at room temperature for 60 min. Sections were again washed with TBS-0.6% Tween 20 prior to application of avidin/biotin peroxidase detection system (ABC-HRP, Dako) for 30 min at room temperature. Immunostaining was subsequently visualized by application of the peroxidase substrate 3,3 ′ -diaminobenzidine (DAB, Dako), which produces a brown precipitate. Tissue sections were counterstained with haematoxylin, dehydrated through ascending grades of ethanol (70-95%) and histosol and mounted with DPX. For assessment of immunohistochemical staining, the amount and intensity of immunostaining within each cellular compartment (glandular and luminal epithelium) was analysed by two independent reviewers and allocated a score: 0 (no staining); 1 (minimal staining); 2 (strong staining); 3 (intense staining).
Galectin-7 ELISA
The concentration of galectin-7 in menstrual fluid, peripheral blood plasma, and conditioned media was determined by ELISA (Raybio w Human Galectin-7 ELISA # ELH-Galectin7-001) as per the manufacturer's instructions. The ELISA shows no cross reactivity with any tested cytokines with detection of galectin-7 between ,20 and 10 000 pg/ml. Menstrual fluid and peripheral blood plasma were diluted 1:5 in diluents (provided). Cell culture media was added undiluted to the assay plate.
Primary human stromal cell isolation
Endometrial stromal cells from five women were isolated from endometrial curettage samples according to standard protocols. Briefly, endometrial tissue was chopped and incubated in phosphate buffered saline (PBS, Invitrogen, Mulgrave, VIC, Australia) containing collagenase III (7.5 IU/ml, Sigma, Sydney, NSW, Australia) and DNAse I (100 mg/ml, Worthington, Lakewood, NJ, USA) at 378C with shaking at 130 rpm for 40 min. Digestion was stopped by addition of excess DMEM/F12 (Invitrogen). Digested samples were sequentially vaccum filtered through 45 and 11 mm filters before collection of the stromal cell pellet by centrifugation. Cells were sequentially seeded in DMEM/F12 media containing 10% charcoal-stripped fetal calf serum (csFCS, Invitrogen) and 1% penicillin/streptomycin (p/s), into sterile cell culture flasks for 25 min to allow cell attachment before removal of blood contamination (Dimitriadis et al., 2002) . Cells were allowed to grow for 4 days before seeding into 9 × 3 cm dishes, and then allowed to settle and achieve confluency for 2 days. Stromal cells were visually checked for the presence of contaminating epithelial cells and discarded if such cells were present (Evans and Salamonsen, 2013) .
Decidualization and 'menstrual mimic' hormone withdrawal
The models used were previously described (Evans and Salamonsen, 2013) . Briefly, decidualization (n ¼ 5 cell preparations from different women) was performed using DMEM/F12 media containing 2% csFCS/1% p/s and the decidualization stimulus [17b-estradiol (E2, 10 28 M, Sigma) and MPA (10 27 M, Sigma)] with media change every 2 days for 12 days. Hormones were then withdrawn by washing the cells with PBS and adding fresh DMEM/F12 media containing 2% csFCS/1% p/s only. Photographs of cellular morphology were taken at Days 2, 9 and 12 of decidualization and 2 days after hormone withdrawal. Conditioned media were collected from hormone-treated cells on Days 2, 9 and 12 of decidualization and on Days 1 -4 after hormone withdrawal. Prolactin (PRL) assay was performed to assess the extent of decidualization and galectin-7 ELISA was performed as indicated above.
Prolactin assay
PRL assays were performed at Southern Health pathology using the Access/ DXI PRL assay, which is a simultaneous one-step immunoenzymatic (sandwich) assay carried out on a Beckman Coulter Unicel DXI 800. Briefly, the culture media sample was added to a reaction vessel along with polyclonal goat anti-PRL-alkaline phosphatase conjugate and paramagnetic particles coated with mouse monoclonal anti-PRL antibody. The sample PRL binds to the monoclonal anti-PRL on the solid phase, while the goat anti-PRL-alkaline phosphatase conjugate reacts with a different antigenic site on the cell culture PRL. After incubation in a reaction vessel the sample is subjected to separation in a magnetic field and washing to remove materials not bound to the solid phase. A chemiluminescent substrate, Lumi-Phos* 530, is added to the reaction vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of PRL in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve. The analytical range of the assay is 5.3 -4240 mIU/l.
Endometrial epithelial cell culture
Endometrial epithelial cell (ECC-1) cells were routinely maintained in a 1:1 mix of DMEM:F12 (Gibco, Invitrogen) supplemented with 1% p/s and 10% FCS (Gibco, Invitrogen). ECC-1 cells were chosen as they closely resemble primary human endometrial epithelial cells and are representative of the luminal epithelium (Hannan et al., 2009 ).
Wounding assays
Cells were plated at 1 × 10 6 cells per well of a 6-well plate (for wound healing assays) or 5 × 10 4 cells per well of a 96-well plate (for ECM arrays and PCR validation) and grown to over-confluence for 72 h. They were deprived of serum (starved) for 24 h before wounding using vacuum suction through a Prot/Elec pipette tip. On the day of wounding, designated Day 0 (d0), cell wounds were photographed using a Motic AE31 inverted microscope and camera and Motic Images plus2.0 (Motic microscopy, Hong Kong), this was repeated every 24 h for up to 3 days. Medium was substituted with PBS for photographing, and then replaced. To assess differences in repair, the area of each cell wound was quantified using Motic Images plus2.0 Imaging Software on d0 and on each subsequent day, with data expressed as percent repair versus d0. For each experiment, at least six wounds were assessed per individual treatment. Treatments are presented as mean + standard error of the mean (SEM) of at least four separate experiments. Treatments used included Bovine Serum Albumin (BSA) at an equivalent dilution to galectin-7 (vehicle control), 2.5 mg/ml recombinant galectin-7 (dose chosen after initial dose-response studies, R&D systems), RGDS (arg-glyasp-ser) and RGES (arg-gly-glu-ser, both Sigma Aldrich each at final concentration of 25 mM). These doses were chosen after preliminary experiments.
RNA extraction
RNA was extracted from wounded cell monolayers (across a time course of 3 days) with TRI-reagent (Sigma Aldrich) following the manufacturer's guidelines. Briefly, cells were homogenized in TRI-reagent and lysates transferred to phase lock tubes followed by addition of 1-bromo-2-chloropropane. Samples were centrifuged to separate organic and inorganic phases followed by transfer of the upper phase to an RNAse free tube. 2-Propanol was added prior to overnight storage at 2808C. RNA was precipitated by centrifugation followed by washing of the RNA pellet in 70% ethanol and re-suspension of RNA in RNAse free water. The RNA concentration was assessed using a nano-drop spectrophotometer and the RNA quality assessed using Experion RNA chips (BioRad, Gladesville, NSW) prior to processing for array or realtime RT-PCR analysis. RNA was not found to be degraded prior to processing for array or RT-PCR.
RT 2 -PCR arrays
Briefly, as indicated above, 5 × 10 4 cells per well were seeded in 6 wells of a 96-well plate for each treatment (2.5 mg/ml recombinant galectin-7 or BSA vehicle control). Cells were grown to over-confluence for 72 h, deprived of serum for 24 h, wounded and treated with 2.5 mg/ml recombinant galectin-7 or BSA (vehicle control). Cell treatment were terminated by removal of media and addition of TRI-reagent on Day 0 (baseline time-point, cells wounded, no treatment added), and on Days 1, 2 and 3. The six experimental replicate wells for each treatment were pooled for each day and RNA extracted as described above. This was repeated five times (n ¼ 5 individual repeats). RNA was subjected to pathway-focused PCR gene array analysis (PAHS-013Z, SABiosciences) to examine expression of ECM factors. Initially, genomic DNA contamination was eliminated from the RNA samples using a genomic DNA elimination kit according to the manufacturer's protocol (SABiosciences). Subsequently, first strand cDNA synthesis reaction was performed using 1 mg RNA. RNAse free water was added to the cDNA followed by storage at 2208C. A PCR mastermix was prepared using the individual cDNAs and Power Sybr green mastermix (ABI). 25 ml of mastermix was added to each well of the 96-well array plate and reactions were run on an Applied Biosystems 7900 HT-Fast Real-Time PCR machine following the programme of heating to 958C for 10 min and 40 cycles of 15 s at 958C and 1 min at 608C. Data were analysed using the 2 Ct method with all data normalized against GAPDH expression. All data that did not yield detectable signals were removed from the analysis. No genomic contamination Galectin-7 mediates endometrial repair was noted for any PCR plate. In brief, gene expression in BSA-treated cells on Days 1 and 3 was compared with Day 0 to determine basal changes across a time course of repair. Gene expression in galectin-7-treated cells was compared with BSA vehicle control on the same day to determine changes in ECM gene expression mediated by galectin-7 treatment. Data from BSA-treated cells were expressed as percentage change versus Day 0 (with Day 0 set as 100%) to determine basal changes in ECM gene expression across a time course of repair. Data from galectin-7-treated cells were expressed as percentage change versus BSA-treated cells (with BSA treatment on that day set as 100%) on the same day to determine changes mediated by galectin-7 across a time course of repair. Statistical analysis was not performed on array data but was performed on real-time PCR validation data (below).
Real-time PCR
Validation of gene array data (six pooled wells from each treatment/each day, n ¼ 5 individual experiments) was performed by real-time PCR analysis. Briefly, 250 ng of RNA was reverse transcribed to prepare cDNA. A PCR mastermix was prepared using sybr green mastermix (ABI) and primers for CNTN1, CTNNB1, TNC, TGFB1 or 18 s (Primer sequences given in Table I , TGFB1 as used in (Bilandzic et al., 2009) . The mastermix and sample cDNA was individually mixed and added to 384-well plates in triplicate. Reactions were run on an Applied Biosystems 7900 HT-Fast Real-time PCR machine following the programme of heating to 958C for 10 min and 40 cycles of 15 s at 958C and 1 min at 608C. Data were analysed using the 2 Ct method with all data normalized against 18 s expression (run on each plate). Galectin-7 data were expressed as fold-change versus BSA (vehicle control) treatment for each day.
Statistical analysis
All statistical analyses were performed using PRISM version 4.03 for windows. All data were tested for normality prior to analysis. In the case of normally distributed data, an unpaired t-test was applied. In the case of nonnormally distributed data a Mann -Whitney test was performed. Significance was taken as P , 0.05. All data are presented as mean + SEM.
Results
Endometrial galectin-7 is down-regulated in women with amenorrhoea
Immunohistochemistry revealed intense galectin-7 immunostaining in the glandular (arrows, Fig. 1A and E, B and F) and luminal epithelial cells during the late secretory phase of the menstrual cycle. In very late secretory phase endometria that show evidence of tissue fragility or focal breakdown (asterisk, Fig. 1B ), galectin-7 also localized strongly to the decidualized stroma (open arrowhead, Fig. 1B ).
Intense immunostaining for galectin-7 was also observed in menstrual phase endometria. Galectin-7 localized to the glandular epithelium (arrows, Fig. 1C and G, D and H) , luminal epithelium (closed arrowhead, Fig. 1C ) and decidualized stroma (open arrowhead, Fig. 1C and D) in tissues undergoing breakdown. In menstrual tissues and late secretory tissues, galectin-7 localization appeared to be mainly cytoplasmic (arrows, Fig. 1E -H) .
In the endometria of women with amenorrhoea, galectin-7 staining was absent ( Fig. 1L and P) , weak ( Fig. 1I and M) or patchy ( Fig. 1J and N, K and  O) . Semi-quantitative scoring of late secretory (n ¼ 6), menstrual (n ¼ 9) and amenorrhoea (n ¼ 10) endometria revealed a significantly lower galectin-7 immunostaining in the glandular (late secretory and menstrual phases; Fig. 1I ; P , 0.05) and luminal (late secretory phase; Fig. 1J ; P , 0.05) epithelium of women with amenorrhoea compared with women with normal repair. Menstrual luminal epithelium could not be compared as very few menstrual sections exhibited luminal epithelium.
Progesterone withdrawal does not induce galectin-7 production by decidualized stromal cells in vitro Localization of galectin-7 to decidualized stromal cells was only observed in very late secretory endometrium in which some degree of focal breakdown was apparent (Fig. 1B) . To determine whether expression of galectin-7 in these cells was associated with hormone withdrawal as occurs immediately prior to menses, primary human stromal cells were decidualized for 12 days followed by hormone withdrawal for 4 days. Alteration in cell morphology ( Fig. 2A) and an increase in PRL secretion was observed across the time course of decidualization (Fig. 2B ). This was followed by a decrease in PRL secretion upon hormone withdrawal (Fig. 2B) . No alteration in secretion of galectin-7 into the culture media by decidualized stromal cells after withdrawal of hormones was observed in vitro (Fig. 2C) .
Endometrial galectin-7 accumulated in menstrual fluid ELISA analysis revealed that levels of galectin-7 in menstrual fluid collected on Day 2 of menses were significantly higher compared with matched peripheral blood plasma (same woman, same day, n ¼ 6, Fig. 3A , P , 0.01). Gross observations of menstrual volume collected (ml) were correlated with normalized menstrual fluid galectin-7 concentration (pg/mg). No correlation was observed between the volume of menstrual fluid collected and the concentration of galectin-7 (Fig. 3B) .
Galectin-7 promoted endometrial re-epithelialization 
Table I
Primer sequences for contactin (CNTN1), tenascin c (TNC), b-catenin (CTNNB1), TGF-b1 and 18 s.
Primer
Forward Reverse Figure 1 Immunoreactive galectin-7 in peri-menstrual endometria of normal cycling women and in those with amenorrhoea. Galectin-7 localized to the glandular epithelial cells of late secretory normal cycling endometria (arrows, A and B) with a mainly cytoplasmic localization (arrows, E and F), with decidual localization also noted in late secretory normal cycling endometria (open arrowhead, B) in combination with evidence of focal tissue breakdown (*, B). In menstrual phase normal cycling endometrium, galectin-7 localized to the glandular epithelium (arrows, C and D), with localization observed to be mainly cytoplasmic (arrows, G and H) luminal epithelium (closed arrowhead, C) and the degrading stroma (*, G). In the amenorrhoeal non-cycling endometria, galectin-7 localized mainly to the glandular epithelium (arrows, I-L, M-P, tissues presented in panels I, J, M and N taken from women with PCOS). Semi-quantitative scoring revealed significantly lower staining intensity for glandular epithelial galectin-7 in the non-cycling amenorrhoeal endometria versus the late secretory and menstrual normal cycling endometrium (Q) and significantly lower staining intensity for luminal epithelial galectin-7 in the amenorrhoeal endometrium versus the late secretory endometrium (R). Data presented as mean + SEM. *P , 0.05. Inset in panels 1A-1D and 1I-1L, IgG-negative control. n ≥ 5 per cycle stage.
Galectin-7 mediates endometrial repair were wounded and treated with exogenous galectin-7 (2.5 mg/ml) or vehicle control (BSA) for 3 days. Treatment with galectin-7 (Fig. 4A ) significantly enhanced endometrial repair versus vehicle control (BSA, Fig. 4A ) over a time course of repair (*P , 0.01).
Galectin-7 facilitated endometrial re-epithelialization was dependent on ECM-integrin interactions
To investigate the mechanism by which galectin-7 mediates enhanced wound repair, epithelial cell monolayers were co-treated with galectin-7 (or vehicle control) and the RGDS peptide or control (RGES peptide) to inhibit integrin -fibronectin interaction. The RGDS peptide significantly impaired galectin-7 mediated re-epithelialization ( Fig. 4F ; P , 0.05) whereas the control RGES peptide had no effect on galectin-7 mediated re-epithelialization (Fig. 4G ).
Galectin-7 enhanced basal extracellular matrix changes over a time course of repair
Repair of wounded endometrial epithelial cell monolayers was accompanied by elevation in gene expression of 26 ECM factors (Table II) . Many of these ECM factors were further elevated upon treatment with 2.5 mg/ml recombinant galectin-7, with 16 ECM factors demonstrating a . 130% increase in expression over that mediated by BSA on at least 1 day (indicated by bold, Table III ). 
Galectin-7-mediated elevation of additional ECM factors over a time course of repair
In addition to enhancing the expression of ECM factors which are up-regulated basally across a time course of wound repair (Table III) , treatment with 2.5 mg/ml recombinant galectin-7 mediated elevated expression of ECM factors not altered during wound repair under control conditions (Table IV , bold indicate .130% increase in expression versus BSA treatment on the same day). Change in expression of additional ECM factors mediated by galectin-7 included ADAMTS13, CDH1, CNTN1, CTNNB1, FN1, ITGA1, ITGA6, ITGA8, ITGAV, TGFB1 and TNC. Galectin-7-mediated elevation of 4 ECM factors was subsequently validated by quantitative real-time PCR (Q-RT -PCR). Elevated CNTN1 (Fig. 5A) , TNC (Fig. 5B) , CTNNB1 (Fig. 5C ) and TGFB1 (Fig. 5D ) expression by galectin-7 was observed over a time course of repair (*P , 0.05).
In the array data (Table IV) , CNTN1 was observed to be elevated by galectin-7 treatment .130% on both Days 1 and 3 of repair. By Q-RT-PCR analysis, CNTN1 was elevated by galectin-7 treatment on all days of wound repair (Days 1-3 inclusive, significantly on Day 1, *P , 0.05). TNC was elevated by .130% on Day 1 as determined by pathway-focused gene array. TNC expression was induced by galectin-7 on Days 1-3 inclusive by Q-RT-PCR, although these data were not statistically significant. Although not statistically significant, this elevation could play a physiologically significant role. A limitation of these assays is that the wound edge, at which changes in gene expression would be occurring in concert with cell proliferation and locomotion as part of repair, represents only a very small proportion of the total cells within the well, meaning that relatively small changes can still have significant implications in terms of cell function. On the pathway-focused array, CTNNB1 was observed to be elevated .130% by galectin-7 treatment on Days 1 and 3. However, by Q-RT-PCR, CTNNB1 was observed to be elevated on Days 1 and 2 only (*P , 0.05). By array analysis, TGFB1 was elevated on Day 1 of treatment with galectin-7, with Q-RT-PCR analysis in agreement identifying elevated expression of TGFB1 on Days 1 and 2 of treatment (*P , 0.05).
Discussion
Post-menstrual repair of the endometrium is a very rapid process requiring interaction between the migrating epithelium and the underlying stroma to facilitate re-epithelialization and terminate bleeding. This process is dependent on a variety of growth factors (Fan et al., 2008; Kaitu'u-Lino et al., 2009; Maybin et al., 2011a, b) and dynamic ECM interactions (Evans et al., 2011) to facilitate cell proliferation, migration and re-epithelialization. Here, we demonstrate that the endometrium produces and actively secretes galectin-7 during the late secretory and menstrual phases of the menstrual cycle, to accumulate within menstrual fluid. Galectin-7 contained within menstrual fluid likely acts in a paracrine manner to elevate expression of ECM factors and facilitate re-epithelialization. This study demonstrates the presence of galectin-7 within the menstruating endometrium. During the secretory phase of the menstrual cycle, the endometrial epithelium actively secretes a host of factors which accumulate within uterine fluid (Hannan et al., 2011 (Hannan et al., , 2012 . Localization to the glandular epithelium (Menkhorst et al., 2014) and its presence within menstrual fluid suggests galectin-7 is actively secreted by the endometrium. Galectin-7 localized to decidualized stromal cells only within the very late secretory and menstrual phase endometrium. While Menkhorst et al. (2014) observed limited immunostaining in the endometrial stroma of women who had experienced miscarriage, this is the first report of localization to decidualized stromal cells in the very late secretory phase endometrium These stromal cells have transformed from a fibroblast-like morphology to epithelioid-like under the influence of progesterone during the secretory phase of the menstrual cycle. It is known that decidualized cells actively secrete a host of factors (Paule et al., 2011) , much like endometrial epithelial cells at this stage of the menstrual cycle. However intriguingly, we only observed decidual galectin-7 in tissues showing focal areas of breakdown (see Fig. 1B ). Given that galectins-1, -3 and -15 are hormonally regulated in the endometrium and placenta (Jeschke et al., 2013) , and the immunolocalization of galectin-7 to decidualized stromal cells only at the time of initial tissue breakdown immediately prior to menses, we investigated whether galectin-7 is likewise hormonally regulated in stromal cells. Using an in vitro model of breakdown in which stromal cells were decidualized with estrogen and progesterone and then subjected to hormone withdrawal thus mimicking corpus luteum demise at menses (Evans and Salamonsen, 2013) , we showed that galectin-7 production and secretion by Figure 3 Galectin-7 accumulates in menstrual fluid, is elevated versus matched peripheral blood plasma and does not correlate with volume of menstrual fluid loss. Galectin-7 (pg/mg protein) in menstrual fluid and matched peripheral blood plasma (same woman, same day) demonstrates significant elevation in menstrual fluid (A). Galectin-7 concentration in menstrual fluid (pg/mg) does not correlate with gross observations of menstrual fluid volume (ml) collected (B). Data presented as spread of data from seven different women. **P , 0.01.
Galectin-7 mediates endometrial repair decidualized stromal cells was not initiated by hormone withdrawal; however, levels produced by stromal cells were below the reported sensitivity of the galectin-7 ELISA and were therefore calculated by extrapolation of the standard curve. Further, no change in epithelial expression of galectin-7 is observed during the menstrual cycle (Menkhorst et al., 2014) nor change in the endometrium of women with amenorrhoea combined with hormonally influenced conditions such as PCOS (Fig. 1) . We, therefore, speculate that galectin-7 expression by decidualized stromal cells is regulated by other factors in the endometrium during breakdown, possibly factors associated with the influx of leukocytes into the endometrium (e.g. chemokines and cytokines) at that stage of the menstrual cycle. Additionally, changes in oxygen tension within the endometrium Figure 4 Galectin-7 enhances in vitro endometrial repair in a fibronectin-integrin-dependent manner. ECC-1 cells were grown to over-confluence, wounded on Day 0 (A) and in vitro repair monitored over Days 1 (B), 2 (C) and 3 (D), with wound areas measured on each day. Treatment of wounded ECC-1 monolayers with 2.5 mg/ml recombinant galectin-7 (E, B) enhanced in vitro repair versus vehicle control (B, BSA). Co-treatment of wounded ECC-1 monolayers with galectin-7 and RGDS (F, B) reduced the extent of repair compared with galectin-7 treatment alone. Co-treatment of wounded ECC-1 monolayers with galectin-7 and RGES (G, B) had no effect on the extent of repair compared with galectin-7 treatment alone. Data presented as mean + SEM, representative of four individual experiments with six replicates within each experiment. *P , 0.05. at this stage of the menstrual cycle, associated with vasoconstriction during the immediate premenstrual phase (Kelly et al., 2002) may regulate galectin-7 in a similar manner to hypoxic regulation of other galectins (Zhao et al., 2010 (Zhao et al., , 2011 Cho et al., 2012) . However, we cannot exclude the possibility that regulation in vivo is due to a complex interplay of paracrine and autocrine signalling factors produced by the surrounding endometrial cells. It may well be that secretion of galectin-7 by stromal cells in culture is not possible in the absence of signals produced by endometrial leukocytes and glandular epithelial cells during the menstrual phase of the cycle.
Active secretion of galectin-7 by the endometrium immediately prior to, and during, the menstrual phase of the cycle results in significant levels of galectin-7 within the menstrual fluid (versus peripheral blood plasma), which is a combination of endometrial secretions, endometrial tissue and blood . Peripheral blood plasma was used as a comparator to control for blood-derived versus endometrial-derived factors present within the menstrual fluid. Importantly, the endometrium is bathed in menstrual fluid at the time that endometrial repair is initiated in vivo. We did not find any correlation between the volume of menstrual blood loss and galectin-7 levels in menstrual fluid (Fig. 3B) . It is possible that, due to the small sample size used in this study, any correlation that does exist may have been missed. However, this study does demonstrate that use of a menstrual cup provides a semi-quantitative measurement of menstrual blood loss within the specific time period over which menstrual fluid was collected. No women in our study reported leakage while using the menstrual cup and all women were able to pour the collected menstrual fluid into a graduated collection tube without spillage; therefore, the entire amount of menstrual fluid captured by the cup during the 6 h collection period was provided to researchers. Interestingly, only the subject who provided a menstrual fluid sample with a volume of 17.5 ml (Fig. 3B) had (self-reported) menorrhagia. This study did not aim to determine whether participants had menorrhagia based on the volume of the provided menstrual fluid sample. Pictogram assessments of menstrual blood loss (Wyatt et al., 2001) could be used in association with measurements of galectin-7 levels in menstrual fluid; however, this would be a complex study to analyse as the time period during which the Galectin-7 mediates endometrial repair woman was wearing the menstrual cup would preclude collection of pictogram data, the measured volume collected by menstrual cup could however be added to pictogram assessments for an approximate of total menstrual blood loss during menstrual bleeding and may give a clearer picture than correlation with volume collected during the 6 h period of menstrual cup use. We have demonstrated previously that menstrual fluid derived factors facilitate endometrial repithelialization in vitro. Given galectin-7 has a demonstrated role in repair of epithelia including cornea, skin and kidney epithelium (Cao et al., 2002 (Cao et al., , 2003 Gendronneau et al., 2008; Rondanino et al., 2011) , we propose that the elevated levels of galectin-7 in menstrual fluid could act in a paracrine manner to facilitate endometrial repair. Indeed, we demonstrate clearly that galectin-7 facilitates endometrial repair in vitro. Interestingly, women with amenorrhoea, who do not experience endometrial breakdown and repair, appear to have little galectin-7 within their endometrium, suggesting that normal menstrual cycling is important for appropriate expression and production of galectin-7 within the endometrium. This is reflected in conditions of abnormal skin repair in which galectin-7 is down-regulated (Cho et al., 2013) .
Blocking integrin -fibronectin interactions significantly inhibited galectin-7-mediated endometrial re-epithelialization in vitro. However, it is not clear from these data, if galectin-7 simply utilizes these integrin -ECM interactions or actively enhances the interactions by elevating expression of ECM factors; certainly galectin-7 regulates integrin a1 in HeLa cells . Therefore, we investigated whether galectin-7 regulated ECM expression by microarray. Galectin-7 enhanced basal changes of a number of these across a time course of repair and also induced expression of additional ECM factors. In agreement with Kuwabara et al. (2002) , galectin-7 regulated integrin expression in endometrial epithelial cells. Integrin -fibronectin interaction is essential for galectin-7-mediated endometrial repair (Fig. 4) ; however, galectin-7 treatment changed fibronectin expression only marginally, suggesting fibronectin plays a permissive rather than an active role in galectin-7-mediated endometrial repair. We have previously demonstrated the importance of basal changes in fibronectin expression during endometrial repair (Evans et al., 2011) . Changes in CNTN1, CTNNB1 and TGFB1 were validated by Q-RT-PCR. While these changes are relatively small, it must be noted that the wound edge, where these changes would be taking place, is a relatively small area in relation to the size of the cell culture plate well: thus, large changes in ECM expression would not be expected in this system. Overall, these data suggest that galectin-7 enhances expression of ECM factors to facilitate re-epithelialization. The ECM factors regulated by galectin-7 have also been implicated in repair in other tissues. CNTN1, via interaction with integrins is proposed to play a role in repair in the CNS (Laursen et al., 2009 ). In the lung epithelia, activation of CTNNB1 plays an essential role in repair after injury (Flozak et al., 2010; Zemans et al., 2011) ; it is increasingly apparent that there are a number of similarities between the lungs and the endometrium (both mucosal epithelia) in terms of protein production and activation (Hannan et al., 2010) . TGF-b has long been known as a key cytokine promoting wound repair in many tissues (Branton and Kopp, 1999) . Galectin-7 also mediated down-regulation of mRNA for ECM factors, particularly MMP1 and MMP15; whether this is reflected in their protein or activity levels needs to be established. Since MMPs, and particularly MMP1 are critical for endometrial breakdown (Evans and Salamonsen, 2012 ), galectin-7 may limit further endometrial shedding concurrently with mediation of endometrial repair. Importantly, this is the first report of gene regulation by galectin-7 at the mRNA level, and these data may suggest that galectin-7 binding to an as yet unknown receptor on the cell surface can mediate activation of intracellular signalling cascades to initiate RNA transcription.
Given the positive contribution of galectin-7 to endometrial repair, it presents a potential treatment for dysfunctional uterine bleeding (DUB). DUB is bleeding that is abnormal in timing or quantity and not associated with any pathology and is likely to result from inadequate repair mechanisms (Evans and Salamonsen, 2012) . Thus, factors that enhance endometrial repair may be useful as therapeutics to terminate bleeding episodes in women who experience DUB.
In conclusion, galectin-7 is produced by the premenstrual and menstrual endometrium, where it accumulates in menstrual fluid and likely acts as a paracrine factor to facilitate post-menstrual endometrial re-epithelialization. Galectin-7-mediated re-epithelialization was dependent on integrin mediated signalling and elevated the expression of ECM factors which are involved in repair in other tissues. Galectin-7 is a candidate for a growth factor which likely plays a significant role in postmenstrual endometrial repair.
